Tarsus is a late-stage biopharmaceutical company focused on developing therapies for ophthalmology conditions.
Tarsus’ lead pipeline candidate, TP-03, is attempting to treat Demodex blepharitis. This treatment has completed four phase 2 trials to date. It expects to launch a phase 2b/3 trial in September.
Tarsus was founded in 2016.
More articles on surgery centers:
12-OR ASC part of $295M Florida orthopedic hospital expansion
3 ASCs launching total joint programs
4 ASCs installing total joint robots
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.